Abstract 5820
Background
DNA sequencing to identify variants is becoming increasingly valuable in clinical settings; including matching patients to approved targeted therapies, immunotherapies, and/or clinical trials. However, accurate calling of genetic variants from sequencing still remains challenging. With little corroboration between the different tools available, patients are at risk of being treated with therapies that are unsuitable for their cancer.
Methods
Here we present a novel machine learning based method for the accurate identification of somatic variants in cancer patient tumour samples, with a neural network architecture from encoded raw sequencing read information of tumour/normal sample pairings into an image, enabling it to classify whether a variant is germline, somatic, or sequencing error. The model was trained and tested on in-silico spike-in data using bam-surgeon, and then validated on a multi-cancer and multi-center dataset and benchmarked against industry standard variant callers.
Results
The approach, called somaticNET, outperforms existing industry standard tools in sensitivity and specificity, achieving an AUROC of ∼1.00 on the bam-surgeon dataset and an AUROC of ∼0.99 on the multi-cancer multicenter dataset. The model also works faster than other variant callers, in minutes compared to hours.
Conclusions
Using the power of machine learning for accurate somatic variant calling can improve patient matching to approved therapies and clinical trials, thus ensuring patients are given the right therapy at the right time to treat their cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cambridge Cancer Genomics.
Disclosure
G. Dubourg-Felonneau: Shareholder / Stockholder / Stock options, Full / Part-time employment: Cambridge Cancer Genomics. D. Rebergen: Shareholder / Stockholder / Stock options, Full / Part-time employment: Cambridge Cancer Genomics. C. Parsons: Shareholder / Stockholder / Stock options, Full / Part-time employment: Cambridge Cancer Genomics. H. Thompson: Shareholder / Stockholder / Stock options, Full / Part-time employment: Cambridge Cancer Genomics. J.W. Cassidy: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Cambridge Cancer Genomics. N. Patel: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Cambridge Cancer Genomics. H.W. Clifford: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Cambridge Cancer Genomics.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract